JPWO2020181164A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181164A5 JPWO2020181164A5 JP2021552935A JP2021552935A JPWO2020181164A5 JP WO2020181164 A5 JPWO2020181164 A5 JP WO2020181164A5 JP 2021552935 A JP2021552935 A JP 2021552935A JP 2021552935 A JP2021552935 A JP 2021552935A JP WO2020181164 A5 JPWO2020181164 A5 JP WO2020181164A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- domain
- car
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 44
- 102000036639 antigens Human genes 0.000 claims 44
- 108091007433 antigens Proteins 0.000 claims 44
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 37
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 33
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 33
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 25
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 25
- 210000001744 T-lymphocyte Anatomy 0.000 claims 24
- 150000007523 nucleic acids Chemical class 0.000 claims 22
- 210000004027 cell Anatomy 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 15
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 12
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 12
- 230000001939 inductive effect Effects 0.000 claims 12
- 230000004068 intracellular signaling Effects 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 12
- 230000001105 regulatory effect Effects 0.000 claims 11
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 10
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 10
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 10
- -1 CD86 Proteins 0.000 claims 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 102000003735 Mesothelin Human genes 0.000 claims 7
- 108090000015 Mesothelin Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 6
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 6
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 6
- 230000005867 T cell response Effects 0.000 claims 6
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 125000006850 spacer group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 claims 4
- 102000018667 ADP-ribosyl Cyclase 1 Human genes 0.000 claims 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 4
- 102100037904 CD9 antigen Human genes 0.000 claims 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 4
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 4
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 4
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims 4
- 102100025390 Integrin beta-2 Human genes 0.000 claims 4
- 108010052781 Interleukin-3 Receptor alpha Subunit Proteins 0.000 claims 4
- 102000018883 Interleukin-3 Receptor alpha Subunit Human genes 0.000 claims 4
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 4
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 102000024905 CD99 Human genes 0.000 claims 2
- 108060001253 CD99 Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 2
- 101000740462 Escherichia coli Beta-lactamase TEM Proteins 0.000 claims 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 229930186217 Glycolipid Natural products 0.000 claims 2
- 102100032558 Glypican-2 Human genes 0.000 claims 2
- 102100032530 Glypican-3 Human genes 0.000 claims 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 2
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 claims 2
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 230000006023 anti-tumor response Effects 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000012191 childhood neoplasm Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013601 cosmid vector Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025037065A JP2025108415A (ja) | 2019-03-06 | 2025-03-10 | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814759P | 2019-03-06 | 2019-03-06 | |
| US62/814,759 | 2019-03-06 | ||
| US201962954161P | 2019-12-27 | 2019-12-27 | |
| US62/954,161 | 2019-12-27 | ||
| PCT/US2020/021320 WO2020181164A1 (en) | 2019-03-06 | 2020-03-06 | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025037065A Division JP2025108415A (ja) | 2019-03-06 | 2025-03-10 | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022524507A JP2022524507A (ja) | 2022-05-06 |
| JP2022524507A5 JP2022524507A5 (https=) | 2023-03-13 |
| JPWO2020181164A5 true JPWO2020181164A5 (https=) | 2023-03-13 |
| JP7650809B2 JP7650809B2 (ja) | 2025-03-25 |
Family
ID=70155350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552935A Active JP7650809B2 (ja) | 2019-03-06 | 2020-03-06 | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
| JP2025037065A Pending JP2025108415A (ja) | 2019-03-06 | 2025-03-10 | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025037065A Pending JP2025108415A (ja) | 2019-03-06 | 2025-03-10 | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11969443B2 (https=) |
| EP (1) | EP3934668B1 (https=) |
| JP (2) | JP7650809B2 (https=) |
| CN (2) | CN113924103B (https=) |
| AU (1) | AU2020232789B2 (https=) |
| CA (1) | CA3132660A1 (https=) |
| WO (1) | WO2020181164A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| DK3368571T5 (da) | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| GB201713078D0 (en) | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| CA3174575A1 (en) | 2020-03-02 | 2021-09-10 | The Regents Of The University Of California | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| CA3207861A1 (en) * | 2021-02-11 | 2022-08-18 | Carl H. June | Ccr4-targeting chimeric antigen receptor cell therapy |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| CN114230673A (zh) * | 2021-11-25 | 2022-03-25 | 广州百暨基因科技有限公司 | 融合蛋白及其应用 |
| AU2023314413A1 (en) * | 2022-07-28 | 2025-02-13 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
| CN119907810A (zh) * | 2022-08-26 | 2025-04-29 | 莱蒂恩技术公司 | 用于用全人抗cd20/cd19免疫治疗来治疗癌症的组合物和方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| NL2037809B1 (en) * | 2024-05-29 | 2025-12-12 | Cell Control Biotherapeutics Inc | Loop reinforcement expression system for improved cell therapy products |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| AU2010241864B2 (en) | 2009-04-30 | 2014-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| WO2011038159A2 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| WO2011106723A2 (en) | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
| CN105339498A (zh) | 2013-03-07 | 2016-02-17 | 贝勒医学院 | 癌症中靶向cd138 |
| WO2016138034A1 (en) | 2015-02-24 | 2016-09-01 | The Regents Of The University Of California | Binding-triggered transcriptional switches and methods of use thereof |
| CN114181960B (zh) | 2015-10-09 | 2024-08-23 | 美天施生物科技有限公司 | 嵌合抗原受体和使用方法 |
| US11377637B2 (en) | 2016-04-15 | 2022-07-05 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| EP4282969A3 (en) | 2016-09-02 | 2024-01-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| CA3096798C (en) | 2017-01-09 | 2026-02-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for treating cancer with anti-mesothelin immunotherapy |
| JP7137896B2 (ja) | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| US10442867B2 (en) | 2017-07-31 | 2019-10-15 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| EP3870146A4 (en) * | 2018-10-25 | 2022-08-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Increase or maintaining t-cell subpopulations in adoptive t-cell therapy |
-
2020
- 2020-03-06 CN CN202080034145.7A patent/CN113924103B/zh active Active
- 2020-03-06 US US17/436,432 patent/US11969443B2/en active Active
- 2020-03-06 AU AU2020232789A patent/AU2020232789B2/en active Active
- 2020-03-06 WO PCT/US2020/021320 patent/WO2020181164A1/en not_active Ceased
- 2020-03-06 CA CA3132660A patent/CA3132660A1/en active Pending
- 2020-03-06 EP EP20716630.7A patent/EP3934668B1/en active Active
- 2020-03-06 CN CN202510076766.6A patent/CN119932065A/zh active Pending
- 2020-03-06 JP JP2021552935A patent/JP7650809B2/ja active Active
-
2024
- 2024-04-02 US US18/624,207 patent/US20240307448A1/en active Pending
-
2025
- 2025-03-10 JP JP2025037065A patent/JP2025108415A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534246A5 (https=) | ||
| JP7462777B2 (ja) | 新規キメラ抗原受容体とその使用 | |
| JPWO2021102337A5 (https=) | ||
| JP2021502070A5 (https=) | ||
| CN107735407B (zh) | 治疗剂 | |
| JP2022502043A5 (https=) | ||
| JP2024055976A (ja) | 細胞 | |
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JPWO2020181164A5 (https=) | ||
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| JP2022522654A (ja) | Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体 | |
| CN116063550A (zh) | 靶向nk激活性受体的嵌合抗原受体 | |
| JP2017512054A (ja) | 三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用 | |
| CN113811327A (zh) | MUC1平行CAR(pCAR)治疗剂 | |
| WO2020143631A1 (zh) | 细胞免疫治疗的组合 | |
| EP4273175A1 (en) | Novel chimeric antigen receptor and use thereof | |
| JPWO2020069184A5 (https=) | ||
| WO2017179015A1 (en) | Compositions for the treatment of cancer | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| CA3125201A1 (en) | Car t cell methods and constructs | |
| EP4186929A1 (en) | Novel co-stimulatory domain and uses thereof | |
| CN115521917A (zh) | 工程化免疫细胞及其用途 | |
| KR20230143108A (ko) | Cd30 유래의 세포내 신호전달 도메인을 포함하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도 | |
| JPWO2022099026A5 (https=) | ||
| WO2023241141A1 (zh) | 靶向ccr8的嵌合抗原受体及其用途 |